Values First Advisors Inc. Purchases 532 Shares of Verona Pharma PLC American Depositary Share $VRNA

Values First Advisors Inc. grew its position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) by 2.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,661 shares of the company’s stock after acquiring an additional 532 shares during the quarter. Verona Pharma PLC American Depositary Share accounts for 1.3% of Values First Advisors Inc.’s portfolio, making the stock its 11th biggest holding. Values First Advisors Inc.’s holdings in Verona Pharma PLC American Depositary Share were worth $2,427,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. bought a new position in shares of Verona Pharma PLC American Depositary Share during the 1st quarter valued at approximately $284,000. Mirae Asset Global Investments Co. Ltd. grew its position in Verona Pharma PLC American Depositary Share by 366.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company’s stock valued at $720,000 after acquiring an additional 9,021 shares during the last quarter. GAMMA Investing LLC grew its position in Verona Pharma PLC American Depositary Share by 14.0% in the 1st quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock valued at $117,000 after acquiring an additional 225 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $389,000. Finally, Harbor Capital Advisors Inc. bought a new position in Verona Pharma PLC American Depositary Share in the 2nd quarter valued at $1,492,000. Institutional investors own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of NASDAQ VRNA opened at $106.91 on Friday. The company has a debt-to-equity ratio of 0.87, a current ratio of 10.71 and a quick ratio of 10.54. The stock has a market capitalization of $9.21 billion, a P/E ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a 1-year low of $31.09 and a 1-year high of $106.93. The business has a fifty day moving average price of $106.21 and a 200 day moving average price of $90.27.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.14. Verona Pharma PLC American Depositary Share had a negative return on equity of 21.12% and a negative net margin of 36.62%.The company had revenue of $103.14 million for the quarter, compared to analyst estimates of $90.41 million. Equities research analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on VRNA shares. Wells Fargo & Company downgraded Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and cut their price objective for the company from $138.00 to $107.00 in a research report on Thursday, July 10th. Truist Financial cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Verona Pharma PLC American Depositary Share in a report on Wednesday, October 8th. Canaccord Genuity Group cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating and set a $107.00 target price for the company. in a report on Wednesday, July 9th. Finally, TD Cowen cut Verona Pharma PLC American Depositary Share from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 9th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $109.00.

Insider Activity at Verona Pharma PLC American Depositary Share

In related news, insider Kathleen A. Rickard sold 58,336 shares of the company’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $766,535.04. Following the transaction, the insider directly owned 2,607,472 shares of the company’s stock, valued at $34,262,182.08. This represents a 2.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO David Zaccardelli sold 208,912 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $13.14, for a total value of $2,745,103.68. Following the transaction, the chief executive officer directly owned 13,376,144 shares in the company, valued at $175,762,532.16. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 540,584 shares of company stock worth $7,103,274 over the last ninety days. Corporate insiders own 4.80% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.